The biggest challenge for the Triangle biopharmaceutical industry continues to be funding on a large scale.
In 2015, venture capital groups poured $676 million into North Carolina companies, of which a good chunk went to biotechnology and other life sciences or health care related companies, according to the PricewaterhouseCoopers MoneyTree Report, a quarterly study of venture capital spending in the United States.
